Association Between Aspirin Use and Biliary Tract Cancer Survival
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2019.4328
Abstract: This database study analyzes the association between aspirin use and survival in patients with biliary tract cancer. read more here.
Keywords: aspirin use; association aspirin; tract cancer; biliary tract ... See more keywords
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01.
Sign Up to like & getrecommendations! Published in 2025 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2025.4736
Abstract: This follow-up analysis of the phase 2 HERIZON-BTC-01 trial evaluates the efficacy, patient-reported outcomes, and safety profile of zanidatamab in patients with ERBB2-amplified biliary tract cancer with a HER2 immunohistochemistry score of 3+ or 2+… read more here.
Keywords: zanidatamab; tract cancer; herizon btc; biliary tract ... See more keywords
A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3813
Abstract: Effective second‐line chemotherapy options are limited in treating advanced biliary tract cancers (BTCs). Resminostat is an oral histone deacetylase inhibitor. Such inhibitors increase sensitivity to fluorouracil, the active form of S‐1. In the phase I… read more here.
Keywords: biliary tract; resminostat; study; histone deacetylase ... See more keywords
Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4593
Abstract: Agents targeting the programmed cell death‐1 pathway have demonstrated encouraging activity across multiple solid tumor types. The dose expansion phase of this phase I study evaluated the safety, tolerability, and antitumor activity of durvalumab monotherapy,… read more here.
Keywords: head neck; durvalumab; tolerability; biliary tract ... See more keywords
Statins associate with lower risk of biliary tract cancers: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4942
Abstract: Biliary tract cancers (BTCs), encompassing cholangiocarcinoma (CCA), gallbladder (GBC), and ampulla of Vater cancers (AVC), are common hepatobiliary cancer after hepatocellular carcinoma with a high mortality rate. As there is no effective chemopreventive agent to… read more here.
Keywords: associate lower; statins associate; tract cancers; biliary tract ... See more keywords
Main causes of death in advanced biliary tract cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5794
Abstract: There are no previous reports on the main causes of death in biliary tract cancer (BTC) patients. This study aimed to evaluate the main causes of death and survival rates in patients with BTC. read more here.
Keywords: causes death; biliary tract; main causes; tract cancer ... See more keywords
Serum 25‐Hydroxyvitamin D Levels and Survival Outcomes in Advanced Biliary Tract Cancer: Results From the NIFTY Trial
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Medicine"
DOI: 10.1002/cam4.70560
Abstract: Numerous studies have explored the role of vitamin D in various cancers; however, its impact on advanced biliary tract cancers (BTC) within a prospective cohort remains to be investigated. This preplanned subgroup analysis of the… read more here.
Keywords: cancer; nifty trial; biliary tract; advanced biliary ... See more keywords
A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer"
DOI: 10.1002/cncr.32964
Abstract: Regorafenib is an oral multikinase inhibitor targeting angiogenesis, oncogenesis, and cancer proliferation/metastasis. This study evaluated the efficacy of regorafenib in refractory biliary tract cancer (BTC) in a multi‐institutional phase 2 study. read more here.
Keywords: biliary tract; regorafenib refractory; tract cancer; multi institutional ... See more keywords
Is there a role for combined anti–PD‐1/CTLA‐4 checkpoint blockade in the management of advanced biliary tract cancers?
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34660
Abstract: Sahai et al. recently reported on a randomized phase 2 trial (BilT‐ 01) investigating chemoimmunotherapy (including the anti–PD‐1 antibody nivolumab) versus combined anti–PD‐1/CTLA‐4 checkpoint blockade (using nivolumab and ipilimumab) in patients with advanced biliary tract… read more here.
Keywords: combination; advanced biliary; tract cancers; treatment ... See more keywords
The rise of biliary tract cancers and next‐generation population registries
Sign Up to like & getrecommendations! Published in 2024 at "Cancer"
DOI: 10.1002/cncr.35284
Abstract: The incidence of biliary tract cancer in Ontario, Canada, is rising, highlighting the urgency of clinical trial enrollment to move the needle in cancer‐specific outcomes. The integration of natural language processing and population registries demonstrate… read more here.
Keywords: generation; rise biliary; population registries; population ... See more keywords
DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer
Sign Up to like & getrecommendations! Published in 2025 at "Cancer"
DOI: 10.1002/cncr.35726
Abstract: This study aims to explore the genetic characteristics of biliary tract cancer (BTC), with a particular focus on the impact of DNA damage response and repair (DDR) genes on clinical outcomes. read more here.
Keywords: dna damage; cancer; tract cancer; damage response ... See more keywords